Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A11 | P48066 | 4/20 | 0.50 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.50 |
| ▸ | KIF11 | P52732 | 7/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.44 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL992028 | 1.00 | SLC6A11 (0.50) | SLC6A11SLC6A1KIF11KCNH2MEN1 | |
| SCHEMBL12199494 | 0.94 | KIF11 (0.51) | SLC6A11SLC6A1KIF11KCNH2MEN1 | |
| SCHEMBL2491594 | 0.93 | SLC6A11 (0.45) | SLC6A11SLC6A1MEN1TP53CYP1A2 | |
| SCHEMBL6040158 | 0.91 | SLC6A11 (0.46) | SLC6A11SLC6A1KIF11KCNH2MEN1 | |
| SCHEMBL2385290 | 0.91 | SLC6A11 (0.46) | SLC6A11SLC6A1KIF11KCNH2MEN1 | |
| SCHEMBL2400336 | 0.91 | SLC6A11 (0.46) | SLC6A11SLC6A1KIF11KCNH2MEN1 | |
| SCHEMBL13575115 | 0.91 | SLC6A11 (0.46) | SLC6A11SLC6A1KIF11KCNH2MEN1 | |
| SCHEMBL334143 | 0.90 | SLC6A11 (0.48) | SLC6A11SLC6A1KIF11KCNH2MEN1 | |
| SCHEMBL8860350 | 0.89 | SLC6A11 (0.47) | SLC6A11SLC6A1KIF11KCNH2MEN1 | |
| SCHEMBL6849984 | 0.88 | SLC6A11 (0.46) | SLC6A11SLC6A1KIF11KCNH2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-10568822-B2 | Melanogenesis inhibitor comprising d-pantothenyl alcohol, and skin-whitening cosmetic containing same melanogenesis inhibitor | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2020-02-25 | — | — | US | disclosed |
| EP-2380567-B1 | MELANIN PRODUCTION INHIBITOR | POLA CHEM IND INC (JP) | 2019-01-16 | — | — | EP | disclosed |
| EP-2380567-B1 | MELANIN PRODUCTION INHIBITOR | POLA CHEM IND INC (JP) | 2019-01-16 | — | — | EP | disclosed |
| US-20170119638-A1 | MELANOGENESIS INHIBITOR COMPRISING D-PANTOTHENYL ALCOHOL, AND SKIN-WHITENING COSMETIC CONTAINING SAME MELANOGENESIS INHIBITOR | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2017-05-04 | — | — | US | disclosed |
| EP-3009123-A1 | MELANIN PRODUCTION INHIBITOR | Pola Chemical Industries Inc. (JP) | 2016-04-20 | — | — | EP | disclosed |
| EP-3009123-A1 | MELANIN PRODUCTION INHIBITOR | Pola Chemical Industries Inc. (JP) | 2016-04-20 | — | — | EP | disclosed |
| US-20150328107-A1 | MELANIN PRODUCTION INHIBITOR | POLA CHEMICAL INDUSTRIES INC. (JP) | 2015-11-19 | — | — | US | disclosed |
| US-20150328107-A1 | MELANIN PRODUCTION INHIBITOR | POLA CHEMICAL INDUSTRIES INC. (JP) | 2015-11-19 | — | — | US | disclosed |
| EP-2845587-A2 | Melanin production inhibitor | Pola Chemical Industries Inc. (JP) | 2015-03-11 | — | — | EP | disclosed |
| EP-2845587-A2 | Melanin production inhibitor | Pola Chemical Industries Inc. (JP) | 2015-03-11 | — | — | EP | disclosed |
| US-20140363389-A1 | MELANIN PRODUCTION INHIBITOR | POLA CHEMICAL INDUSTRIES INC. (JP) | 2014-12-11 | — | — | US | disclosed |
| US-20140363389-A1 | MELANIN PRODUCTION INHIBITOR | POLA CHEMICAL INDUSTRIES INC. (JP) | 2014-12-11 | — | — | US | disclosed |
| US-8846012-B2 | Melanin production inhibitor | POLA CHEMICAL INDUSTRIES INC. (JP) | 2014-09-30 | — | — | US | disclosed |
| US-8846012-B2 | Melanin production inhibitor | POLA CHEMICAL INDUSTRIES INC. (JP) | 2014-09-30 | — | — | US | disclosed |
| EP-2380567-A1 | MELANIN PRODUCTION INHIBITOR | Pola Chemical Industries Inc. (JP) | 2011-10-26 | — | — | EP | disclosed |
| EP-2380567-A1 | MELANIN PRODUCTION INHIBITOR | Pola Chemical Industries Inc. (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-20110243865-A1 | MELANIN PRODUCTION INHIBITOR | POLA CHEMICAL INDUSTRIES INC. (JP) | 2011-10-06 | — | — | US | disclosed |
| US-20110243865-A1 | MELANIN PRODUCTION INHIBITOR | POLA CHEMICAL INDUSTRIES INC. (JP) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170119638-A1 | MELANOGENESIS INHIBITOR COMPRISING D-PANTOTHENYL ALCOHOL, AND SKIN-WHITENING COSMETIC CONTAINING SAME MELANOGENESIS INHIBITOR | MC1R, TYR, NAMPT | SLC6A11 2306/4885SLC6A1 2593/4885KIF11 3669/4885 |
| US-20110243865-A1 | MELANIN PRODUCTION INHIBITOR | TYR, F12, TH | SLC6A11 862/4885SLC6A1 644/4885KIF11 4556/4885 |
| US-10568822-B2 | Melanogenesis inhibitor comprising d-pantothenyl alcohol, and skin-whitening cosmetic containing same melanogenesis inhibitor | MC1R, TYR, NAMPT | SLC6A11 2306/4885SLC6A1 2593/4885KIF11 3669/4885 |
| US-20150328107-A1 | MELANIN PRODUCTION INHIBITOR | TYR, MC1R, F12 | SLC6A11 863/4885SLC6A1 710/4885KIF11 4605/4885 |
| US-20140363389-A1 | MELANIN PRODUCTION INHIBITOR | TYR, F12, MC1R | SLC6A11 1010/4885SLC6A1 801/4885KIF11 4611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.